Alpha Cognition (ACOG) Stock Price, News & Analysis

Company Overview

Alpha Cognition Inc (NASDAQ: ACOG) is a clinical-stage pharmaceutical company focused on the discovery and development of therapies aimed at improving memory and cognitive function in patients with neurological conditions. Leveraging advances in neuropharmacology, the company is developing bespoke compounds that target key pathways implicated in age-related memory loss, Alzheimer’s disease and other forms of dementia.

The lead product candidate, ALPHA-1062, is an investigational extended-release prodrug of a well-established cholinesterase inhibitor. Designed to provide a smoother pharmacokinetic profile and improved tolerability compared with immediate-release formulations, ALPHA-1062 is currently advancing through clinical trials to evaluate its safety, tolerability and cognitive effects in both healthy volunteers and patient populations. In addition, Alpha Cognition’s preclinical pipeline includes novel small molecules that modulate synaptic plasticity and neuroinflammation, with the goal of addressing underlying disease mechanisms.

Founded to translate cutting-edge neuroscience research into practical treatments, Alpha Cognition is headquartered in Westport, Connecticut. The company maintains research collaborations with leading academic institutions and contract research organizations across North America and Europe, positioning its programs for global clinical development and potential commercialization. By combining in-house discovery capabilities with external partnerships, Alpha Cognition seeks to streamline the path from early research through late-stage trials.

Alpha Cognition’s executive leadership team comprises seasoned industry professionals with extensive backgrounds in drug discovery, clinical development and regulatory affairs. The management team is supported by a board of directors and scientific advisory board that includes experts in neurology, pharmacology and translational medicine. Together, they are working to advance new therapeutic options for patients suffering from memory disorders and cognitive decline.

Key Stats

• Today's Range: $9.83 to $10.34
• 50-Day Range: $6.81 to $11.24
• 52-Week Range: $3.75 to $11.54
• Volume: 29,132 shs
• Average Volume: 93,980 shs
• Market Capitalization: $160.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Buy

Alpha Cognition Stock Analysis - MarketRank™

Alpha Cognition scored higher than 35% of companies evaluated by MarketBeat, and ranked 755th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Alpha Cognition has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alpha Cognition has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Alpha Cognition is -8.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alpha Cognition is -8.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alpha Cognition has a P/B Ratio of 3.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ACOG.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alpha Cognition does not currently pay a dividend.

Dividend Growth

Alpha Cognition does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ACOG.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Alpha Cognition has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

Search Interest

Only 1 people have searched for ACOG on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alpha Cognition insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.00% of the stock of Alpha Cognition is held by insiders. A high percentage of insider ownership can be a sign of company health.

ACOG Stock Analysis - Frequently Asked Questions

How have ACOG shares performed this year?

Alpha Cognition's stock was trading at $5.86 at the beginning of 2025. Since then, ACOG shares have increased by 70.5% and is now trading at $9.99.

How were Alpha Cognition's earnings last quarter?

Alpha Cognition Inc. (NASDAQ:ACOG) released its quarterly earnings results on Thursday, May, 15th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.58) by $0.38. The company had revenue of $2.93 million for the quarter, compared to the consensus estimate of $0.50 million.
Read the conference call transcript.

When did Alpha Cognition IPO?

Alpha Cognition (ACOG) raised $50 million in an initial public offering (IPO) on Tuesday, November 12th 2024. The company issued 8,695,653 shares at $5.75 per share.

How do I buy shares of Alpha Cognition?

Shares of ACOG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACOG
• CIK: 1655923
• Web: N/A
• Phone: (858) 344-4375
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Alpha Cognition: $20.00
• High Price Target: $20.00
• Low Price Target: $20.00
• Potential Upside/Downside: +94.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.64 million
• Net Margins: N/A
• Pretax Margin: -397.44%
• Return on Equity: -65.83%
• Return on Assets: -48.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.14
• Quick Ratio: 16.83

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.59 per share
• Price / Book: 3.97

Miscellaneous

• Outstanding Shares: 16,020,000
• Free Float: 13,777,000
• Market Cap: $164.53 million
• Optionable: N/A
• Beta: 2.73